keyword
MENU ▼
Read by QxMD icon Read
search

Long acting antipsychotics

keyword
https://www.readbyqxmd.com/read/28449568/bilateral-pretibial-edema-associated-with-paliperidone-palmitate-long-acting-injectable-a-case-report
#1
Erdinc Cicek, Ismet Esra Cicek, Faruk Uguz
Peripheral edema is observed as an adverse effect of the usage of antipsychotics in the literature. This case report describes a 36-year-old female patient with the diagnosis of paranoid schizophrenia who presented with pretibial edema following initiation of long-acting injectable paliperidone palmitate. Pretibial edema developed within the second week of treatment and completely disappeared after its discontinuation.
May 31, 2017: Clinical Psychopharmacology and Neuroscience: the Official Scientific Journal of the Korean College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/28430670/comparison-between-long-acting-injectable-aripiprazole-versus-paliperidone-palmitate-in-the-treatment-of-schizophrenia-systematic-review-and-indirect-treatment-comparison
#2
Chi-Un Pae, Sheng-Min Wang, Changsu Han, Won-Myong Bahk, Soo-Jung Lee, Ashwin A Patkar, Prakash S Masand, Alessandro Serretti, Robin Emsley
We investigated the relative efficacy and tolerability of aripiprazole once monthly (AOM) versus paliperidone palmitate (PP) for treating schizophrenia. Extensive databases searches on short-term, placebo-controlled, randomized studies of AOM and PP were performed. Indirect treatment comparisons were performed between the two long-acting injectable antipsychotics (LAIAs). The primary efficacy endpoint was the mean change in the Positive and Negative Syndrome Scale total score from baseline between each LAIA and placebo...
April 20, 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28424383/-long-acting-injection-four-times-a-year-review-of-the-3-monthly-paliperidone-palmitate-injection
#3
Róbert Herold
Continuous maintenance antipsychotic treatment is one of the most important factor in the long-term course of schizophrenia. Among the therapeutic options available today, the long-acting injectable antipsychotics are those that are able to efficiently provide an optimal treatment strategy required for continuous maintenance treatment. Three-monthly paliperidone palmitate (TREVICTA) is an important milestone in this therapeutic approach, since it is the first and only antipsychotic treatment for patients with schizophrenia, which provides the yearly maintenance therapeutic dose by four injections...
2017: Psychiatria Hungarica: A Magyar Pszichiátriai Társaság Tudományos Folyóirata
https://www.readbyqxmd.com/read/28389342/use-of-mesoporous-cellular-foam-mcf-in-preparation-of-polymeric-microspheres-for-long-acting-injectable-release-formulations-of-paliperidone-antipsychotic-drug
#4
Stavroula Nanaki, Maria Tseklima, Zoe Terzopoulou, Maria Nerantzaki, Dimitrios J Giliopoulos, Konstantinos Triantafyllidis, Margaritis Kostoglou, Dimitrios N Bikiaris
In this study, high surface area mesoporous silica foam with cellular pore morphology (MCF) was used for injectable delivery of paliperidone, an antipsychotic drug used in patients suffering from bipolar disorder. The aim was to enhance paliperidone solubility and simultaneously to prepare long active intractable microspheres. For this reason paliperidone was first loaded in MCF silica and whole system was further encapsulated into PLA and PLGA 75/25 w/w copolymer in the form of microspheres. It was found that paliperidone after its adsorption into MCF was transformed in its amorphous state, thus leading to enhanced in vitro dissolution profile...
April 4, 2017: European Journal of Pharmaceutics and Biopharmaceutics
https://www.readbyqxmd.com/read/28383362/aripiprazole-once-monthly-in-the-treatment-of-acute-psychotic-episodes-in-schizophrenia-post-hoc-analysis-of-positive-and-negative-syndrome-scale-marder-factor-scores
#5
Zahinoor Ismail, Timothy Peters-Strickland, Maia Miguelez, Ross A Baker, Peter Hertel, Anna Eramo, Na Jin, Pamela Perry, Raymond Sanchez, Robert D McQuade, John M Kane
BACKGROUND: Long-acting injectable antipsychotics are treatment options for acute and long-term treatment of patients with schizophrenia. In a previously published 12-week randomized, double-blind, placebo-controlled clinical trial of patients with schizophrenia experiencing an acute psychotic episode, aripiprazole once-monthly 400 mg (AOM 400) produced significantly greater improvement than placebo on the primary endpoint, Positive and Negative Syndrome Scale (PANSS) total score at week 10...
June 2017: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28382557/long-acting-injectable-antipsychotics-in-schizophrenia-literature-review-and-practical-perspective-with-a-focus-on-aripiprazole-once-monthly
#6
REVIEW
Enrico Biagi, Enrico Capuzzi, Fabrizia Colmegna, Alessandra Mascarini, Giulia Brambilla, Alessandra Ornaghi, Jacopo Santambrogio, Massimo Clerici
INTRODUCTION: Prevention of relapse is a major challenge in schizophrenia, a disease characterized by poor adherence to antipsychotic medication leading to multiple rehospitalizations and a substantial burden-of-care. METHODS: We narratively review published clinical data from the development of long-acting injectable (LAI) formulations of antipsychotic drugs and examine the comparative effectiveness of oral versus LAIs in schizophrenia, with a focus on the second-generation LAI antipsychotic aripiprazole...
April 5, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28375050/book-review-antipsychotic-long-acting-injections-antipsychotic-long-acting-injections-2nd-ed-haddad-p-lambert-t-lauriello-j-eds-oxford-oxford-university-press-2016-366pp-isbn-978-0-19-872947-1
#7
Phillip O'Rourke
No abstract text is available yet for this article.
April 2017: Australasian Psychiatry: Bulletin of Royal Australian and New Zealand College of Psychiatrists
https://www.readbyqxmd.com/read/28366115/risk-of-hospitalization-due-to-medication-nonadherence-identified-through-emrs-of-patients-with-psychosis
#8
Carrie E Andrews, Krista Baker, Carolyn J Howell, Arlene Cuerdo, Jamie A Roberts, Abdullah Chaudhary, Stephanie Lechich, Leslie G Nucifora, Dhananjay Vaidya, Ramin Mojtabai, Russell L Margolis, Akira Sawa, Frederick C Nucifora
OBJECTIVE: This study examined whether outpatients with a psychotic disorder who are at risk of hospitalization can be identified by using data from electronic medical records (EMRs). METHODS: Data from EMRs of outpatients enrolled in two clinics for treatment of psychotic disorders were abstracted. Monthly data were collected for 75 patients over two years. The study examined the association of medication nonadherence, substance use, participation in psychiatric rehabilitation, and long-acting injectable antipsychotic use in any given month with the risk of hospitalization in the subsequent month by using generalized estimating equations...
April 3, 2017: Psychiatric Services: a Journal of the American Psychiatric Association
https://www.readbyqxmd.com/read/28361438/drug-utilization-of-japanese-patients-diagnosed-with-schizophrenia-an-administrative-database-analysis
#9
Stephane Cheung, Yukinobu Hamuro, Jörg Mahlich, Takanobu Nakahara, Rosarin Sruamsiri, Sunny Tsukazawa
BACKGROUND AND OBJECTIVE: Patient characteristics require consideration for optimal treatment in order to achieve clinical remission for an improved quality of life and social functioning. Prior evidence supports long-acting injectable antipsychotics (LAIs) in the relapse prevention of schizophrenia. This study aimed to characterize Japanese patients diagnosed with schizophrenia and to compare the outcomes of LAIs and oral antipsychotics (AP) in re-hospitalization or emergency room visit rates...
March 30, 2017: Clinical Drug Investigation
https://www.readbyqxmd.com/read/28360814/long-acting-injectable-risperidone-use-in-an-11-years-old-bipolar-child
#10
Sevcan Karakoç Demirkaya, Süleyman Salih Zoroğlu
Early-onset bipolar disorder is difficult for child psychiatrists in terms of both diagnosis and treatment. The proper diagnostic evaluation is negatively impacted by the atypical clinical manifestation and rapid cycling pattern of the disease, together with common comorbidity with attention-deficit hyperactivity disorder and anxiety disorder. In addition to poor insight, nonadherence to treatment, poor family coping skills, and insufficient child psychiatric inpatient units make clinicians unsuccessful in following up and treating such patients...
December 2016: Noro Psikiyatri Arsivi
https://www.readbyqxmd.com/read/28356723/treatment-patterns-in-medicaid-patients-with-schizophrenia-initiated-on-a-first-or-second-generation-long-acting-injectable-versus-oral-antipsychotic
#11
Dominic Pilon, Kruti Joshi, Neeta Tandon, Marie-Hélène Lafeuille, Rhiannon L Kamstra, Bruno Emond, Patrick Lefebvre
BACKGROUND: Poor antipsychotic (AP) adherence is a key issue in patients with schizophrenia. First-generation antipsychotic (FGA) and second-generation antipsychotic (SGA) long-acting injectable therapies (LAI) may improve adherence compared to oral antipsychotics (OAP). The objective of the study was to compare treatment adherence and persistence in Medicaid patients with schizophrenia initiated on first-generation long-acting injectable therapies (FGA-LAI) or second-generation long-acting injectable therapies (SGA-LAI) versus OAP...
2017: Patient Preference and Adherence
https://www.readbyqxmd.com/read/28350572/aripiprazole-lauroxil-pharmacokinetic-profile-of-this-long-acting-injectable-antipsychotic-in-persons-with-schizophrenia
#12
Marjie L Hard, Richard J Mills, Brian M Sadler, Ryan Z Turncliff, Leslie Citrome
BACKGROUND: Aripiprazole lauroxil is an extended-release prodrug of aripiprazole for intramuscular injection, approved for schizophrenia treatment. We developed a population pharmacokinetic (PopPK) model to characterize aripiprazole lauroxil PK and evaluate dosing scenarios likely to be encountered in clinical practice. METHODS: Data from 616 patients with schizophrenia, collected from 5 clinical studies, were used to construct the PopPK model. The model was subsequently used to evaluate various dose levels and frequency and the impact of dosing delay on aripiprazole concentrations...
June 2017: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28346773/noninterventional-naturalistic-retrospective-study-to-describe-prescription-patterns-of-long-acting-injectable-antipsychotics-and-the-impact-of-introducing-a-new-atypical-antipsychotic-in-the-spanish-province-of-tarragona-catchment-area
#13
Ana M Gaviria, José Franco, Guillem Rico, Gerard Muntané, Cristina Sáez, Vanessa Sánchez-Gistau, Joan de Pablo, Elisabet Vilella
Background: We studied the patterns and predictors of long-acting injectable (LAI) antipsychotic (AP) use in the treatment of schizophrenia and the effect of introducing a new LAI (paliperidone palmitate [paliperidone-LAI]) in the Spanish province of Tarragona. Methods: This noninterventional, naturalistic, retrospective study included electronic medical record data from a large population-based database of 1,646 patients who were diagnosed with schizophrenia according to ICD-10 criteria and treated between January 2011 and December 2013...
March 23, 2017: Primary Care Companion to CNS Disorders
https://www.readbyqxmd.com/read/28342578/efficacy-and-safety-of-aripiprazole-lauroxil-in-schizophrenic-patients-presenting-with-severe-psychotic-symptoms-during-an-acute-exacerbation
#14
Steven G Potkin, Robert Risinger, Yangchun Du, Jacqueline Zummo, Anjana Bose, Bernard Silverman, Srdjan Stankovic, Elliot Ehrich
Aripiprazole lauroxil (AL), a new long-acting injectable antipsychotic, demonstrated safety and efficacy in treating acute exacerbation symptoms of schizophrenia in a 12-week placebo-controlled trial of two doses of AL (441mg and 882mg) administered every 4weeks. We performed a post hoc analysis of this trial to evaluate the efficacy of AL in the subgroup of patients with severe psychotic symptoms, defined as those with baseline Positive and Negative Syndrome Scale (PANSS) Total score above the median score of 92 (n=309)...
March 22, 2017: Schizophrenia Research
https://www.readbyqxmd.com/read/28332704/risk-of-discontinuation-of-antipsychotic-long-acting-injections-vs-oral-antipsychotics-in-real-life-prescribing-practice-a-community-based-study
#15
H Verdoux, E Pambrun, M Tournier, J Bezin, A Pariente
OBJECTIVE: To compare the risk of discontinuation of ambulatory antipsychotic treatment in persons treated with antipsychotic long-acting injections (LAIs) or by oral antipsychotics (OAPs). METHODS: The study was performed in a representative sample of persons newly treated with OAPs (n = 6904) affiliated to the French Insurance Healthcare system. The risk of all-cause discontinuation was compared in patients prescribed OAPs (n = 246) vs. matched patients prescribed LAIs (n = 246) using multivariate survival analyses...
May 2017: Acta Psychiatrica Scandinavica
https://www.readbyqxmd.com/read/28291293/-adverse-effects-of-medication-and-quality-of-life-in-patients-receiving-second-generation-antipsychotics-a-comparison-of-long-acting-injectable-and-oral-therapies
#16
Demet Sağlam Aykut, Filiz Civil Arslan, Ahmet Tiryaki, Evrim Özkorumak, Serdar Karakullukçu
OBJECTIVE: Maintenance treatment with antipsychotic drugs for patients with schizophrenia is highly effective in decreasing the recurrence rate of the disease. In the current study, we aimed to compare long-acting second generation antipsychotic drug injections and oral forms of second generation antipsychotic drugs in terms of their adverse effects on quality of life. METHOD: Forty-one patients receiving second generation antipsychotic drugs and 139 patients diagnosed with schizophrenia or schizoaffective disorder were treated with oral second generation antipsychotic drugs and enrolled in the study...
2017: Türk Psikiyatri Dergisi, Turkish Journal of Psychiatry
https://www.readbyqxmd.com/read/28278537/paliperidone-long-acting-plasma-level-monitoring-and-a-new-method-of-evaluation-of-clinical-stability
#17
Massimo Carlo Mauri, Silvia Paletta, Chiara Di Pace, Alessandra Reggiori, Chiara Rovera, Alessio Fiorentini, Carlo Alfredo Altamura
The second generation long-acting antipsychotics can be a pharmacologic strategy, both in the early phase of illness and in the case of low compliance. The aim of the study was to evaluate the clinical efficacy and tolerability of one monthly injection of paliperidone palmitate (PP1M), paliperidone plasma levels (PLs), and the clinical outcome. 21 outpatients, affected by Schizophrenia or Schizoaffective Disorder, were recruited. PP1M started with 150 mg on day 1 and 100 mg on day 8. Following patients were given a dosage ranging from 50 mg to 150 mg every 28 days...
March 9, 2017: Pharmacopsychiatry
https://www.readbyqxmd.com/read/28260235/no-cognitive-enhancing-effect-of-glp-1-receptor-agonism-in-antipsychotic-treated-obese-patients-with-schizophrenia
#18
P L Ishøy, B Fagerlund, B V Broberg, N Bak, F K Knop, B Y Glenthøj, B H Ebdrup
OBJECTIVE: Schizophrenia is associated with profound cognitive and psychosocial impairments. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are used for diabetes and obesity treatment, and animal studies have indicated cognitive-enhancing effects. In this investigator-initiated, double-blind, randomized, placebo-controlled trial, we tested non-metabolic effects of exenatide once-weekly (Bydureon™) in obese, antipsychotic-treated patients with schizohrenia spectrum disorder. METHOD: Before and after 3 months of exenatide (N = 20) or placebo (N = 20) treatment, patients were assessed with the following: Brief Assessment of Cognition in Schizophrenia (BACS), Rey-Osterreith complex figure test (REY), Short-Form Health Survey (SF-36), Personal and Social Performance Scale (PSP) and the Positive and Negative Syndrome Scale (PANSS)...
March 5, 2017: Acta Psychiatrica Scandinavica
https://www.readbyqxmd.com/read/28258365/dosing-and-switching-strategies-for-paliperidone-palmitate-3-month-formulation-in-patients-with-schizophrenia-based-on-population-pharmacokinetic-modeling-and-simulation-and-clinical-trial-data
#19
REVIEW
Mats O Magnusson, Mahesh N Samtani, Elodie L Plan, E Niclas Jonsson, Stefaan Rossenu, An Vermeulen, Alberto Russu
Paliperidone palmitate 3-month formulation (PP3M), a long-acting injectable atypical antipsychotic, was recently approved in the US and Europe for the treatment of schizophrenia in adult patients who have already been treated with paliperidone palmitate 1-month formulation (PP1M) for ≥4 months. This article reviews the pharmacokinetic rationale for the approved dosing regimens for PP3M, dosing windows, management of missed doses and treatment discontinuation, switching to other formulations, and dosing in special populations...
March 4, 2017: CNS Drugs
https://www.readbyqxmd.com/read/28242474/antiseizure-antidepressant-and-antipsychotic-medication-prescribing-in-elderly-nursing-home-residents
#20
Sai Praneeth R Bathena, Ilo E Leppik, Andres M Kanner, Angela K Birnbaum
OBJECTIVE: The incidence of epilepsy is highest in the elderly and the prevalence of epilepsy is higher in nursing home residents than in other cohorts. Co-medications that act in the central nervous system (CNS) are frequently prescribed in this population. The objective was to identify the most commonly prescribed antiseizure drugs (ASDs) and determine the frequency of use of antipsychotic and antidepressant medications in elderly nursing home residents receiving ASDs. METHODS: Data were obtained from a pharmacy database serving 18,752 patients in Minnesota and Wisconsin nursing homes...
February 24, 2017: Epilepsy & Behavior: E&B
keyword
keyword
81198
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"